Gilead CAR-T placed on partial clinical hold after neurological cases

· Health · United States

Gilead has placed one of its CAR-T therapies on partial clinical hold after several cases of the neurological condition known as ICANS, according to Endpoints News. ICANS, or immune effector cell-associated neurotoxicity syndrome, is a known complication of CAR-T cell therapy. The same report notes that Agios' PDUFA date was pushed back, and includes news about Acumen, Bristol Myers Squibb, Regeneron, Aer Therapeutics and Hemay Pharmaceutical. The partial hold limits certain trial activity for the affected Gilead program while regulators and the company review the neurological events.

Why it matters：A clinical hold on a flagship cell-therapy modality highlights safety scrutiny facing CAR-T developers and could affect trial timelines across the field.

Key points

  • Several ICANS neurological cases preceded the partial clinical hold.
  • Agios' PDUFA date was also pushed back, per the same report.
  • The report also covered Acumen, Bristol Myers Squibb, Regeneron, Aer Therapeutics and Hemay.

Sources (original reporting)

More stories from this day